drugset
drugset / Trial / NCT05429073

A Study of RGLS8429 in Healthy Volunteers

NCT05429073 ↗

Phase 1 Completed 32 enrolled Regulus Therapeutics Inc.
RandomizedSequentialDouble-blindTreatment

Summary

Primary Objective • To assess the safety and tolerability of single ascending doses of RGLS8429 Secondary Objectives * To identify dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of a single SC dose of RGLS8429 * To characterize the pharmacokinetic (PK) properties of RGLS8429

Timeline

Start
2022-06-10
Primary completion
2022-09-08
Completion
2022-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject RGLS8429 Unknown — Subcutaneous

Indications

No indication recorded.